Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
22.61
+1.36 (6.40%)
Mar 9, 2026, 4:00 PM EDT - Market closed

Ultragenyx Pharmaceutical Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-575-569-607-707.42-454.03
Upgrade
Depreciation & Amortization
35362618.2213.24
Upgrade
Asset Writedown & Restructuring Costs
---75.03-
Upgrade
Loss (Gain) From Sale of Investments
-4-13-132248.67
Upgrade
Stock-Based Compensation
153158135130.38104.95
Upgrade
Other Operating Activities
-52-40-21.0911.71
Upgrade
Change in Accounts Receivable
-31-34-23-12.07-5.43
Upgrade
Change in Inventory
-6-11-7-9.7-3.12
Upgrade
Change in Accounts Payable
2447-179.8532.31
Upgrade
Change in Unearned Revenue
-----57.49
Upgrade
Change in Other Net Operating Assets
-1012153.8-29.51
Upgrade
Operating Cash Flow
-466-414-475-380.47-338.7
Upgrade
Capital Expenditures
-6-7-44-116.12-73.09
Upgrade
Cash Acquisitions
----75.03-
Upgrade
Sale (Purchase) of Intangibles
-15-13-3-30-
Upgrade
Investment in Securities
2584221-69.66-121.34
Upgrade
Other Investing Activities
-1-2-6-0.84-0.94
Upgrade
Investing Cash Flow
236-18168-291.65-195.37
Upgrade
Issuance of Common Stock
8639238710.81119.04
Upgrade
Other Financing Activities
39271490.4-0.49
Upgrade
Financing Cash Flow
478399388501.21118.55
Upgrade
Foreign Exchange Rate Adjustments
4-2--1.08-1.19
Upgrade
Net Cash Flow
252-3581-171.98-416.71
Upgrade
Free Cash Flow
-472-421-519-496.59-411.79
Upgrade
Free Cash Flow Margin
-70.13%-75.18%-119.59%-136.68%-117.18%
Upgrade
Free Cash Flow Per Share
-4.79-4.65-7.06-7.10-6.07
Upgrade
Cash Income Tax Paid
4----
Upgrade
Levered Free Cash Flow
-251.13-207-312.54-370.58-244.82
Upgrade
Unlevered Free Cash Flow
-212.38-167.63-271.29-343.7-226.43
Upgrade
Change in Working Capital
-2314-1660.24-63.24
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.